Sol-Gel Technologies Ltd. — Investor Relations & Filings

Sol-Gel Technologies Ltd. is a dermatology company that develops and commercializes topical treatments for skin conditions. The company leverages a proprietary, silica-based microencapsulation technology to stabilize active ingredients and enable controlled drug delivery. Its portfolio includes commercialized products for acne vulgaris and rosacea. The development pipeline focuses on addressing unmet needs in rare dermatological diseases, with a lead candidate, patidegib gel, for the prevention of new basal cell carcinoma lesions in patients with Gorlin syndrome. Other therapeutic areas of interest include pachyonychia congenita and hyperkeratosis-related indications. The company's strategy involves identifying and developing promising dermatological assets to provide innovative formulations for patients.